-$0.35 Earnings Per Share Expected for Akebia Therapeutics Inc (NASDAQ:AKBA) This Quarter

Wall Street brokerages predict that Akebia Therapeutics Inc (NASDAQ:AKBA) will post ($0.35) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Akebia Therapeutics’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.41). Akebia Therapeutics posted earnings of ($0.60) per share in the same quarter last year, which would suggest a positive year over year growth rate of 41.7%. The firm is expected to issue its next earnings results on Wednesday, August 14th.

On average, analysts expect that Akebia Therapeutics will report full-year earnings of ($1.75) per share for the current year, with EPS estimates ranging from ($2.28) to ($1.41). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($1.66) to $0.38. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Akebia Therapeutics.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.02). Akebia Therapeutics had a negative return on equity of 45.06% and a negative net margin of 82.14%. The business had revenue of $72.67 million for the quarter, compared to analysts’ expectations of $83.69 million.

A number of equities research analysts have recently weighed in on AKBA shares. Zacks Investment Research lowered Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 11th. JPMorgan Chase & Co. started coverage on Akebia Therapeutics in a research note on Thursday, May 2nd. They set an “overweight” rating and a $12.00 price target on the stock. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 25th. Citigroup started coverage on Akebia Therapeutics in a research note on Wednesday, March 20th. They set a “neutral” rating and a $9.00 price target on the stock. Finally, BidaskClub upgraded Akebia Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $13.03.

Institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Akebia Therapeutics by 57.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,812 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,835 shares during the period. First Quadrant L P CA acquired a new stake in shares of Akebia Therapeutics during the first quarter worth about $43,000. Great West Life Assurance Co. Can lifted its holdings in shares of Akebia Therapeutics by 80.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 8,418 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 3,743 shares during the period. Caption Management LLC acquired a new stake in shares of Akebia Therapeutics during the first quarter worth about $49,000. Finally, Advisor Group Inc. lifted its holdings in shares of Akebia Therapeutics by 3,206.3% during the fourth quarter. Advisor Group Inc. now owns 9,919 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 9,619 shares during the period. 70.62% of the stock is owned by hedge funds and other institutional investors.

Shares of AKBA stock traded down $0.14 during trading hours on Thursday, reaching $4.16. 14,517 shares of the company’s stock were exchanged, compared to its average volume of 972,397. Akebia Therapeutics has a 1 year low of $4.12 and a 1 year high of $11.60. The firm has a market capitalization of $506.80 million, a price-to-earnings ratio of -1.71 and a beta of 1.51. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.15 and a current ratio of 1.71.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

Featured Article: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on Akebia Therapeutics (AKBA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.